Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that CEO, Josh Disbrow, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.
Aytu BioPharma Disclosure NotificationDENVER, CO / ACCESSWIRE / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIES, AND SETTLEMENT HEARING IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LITIGATION STYLED WITMER V. ARMISTICE CAPITAL LLC, ET AL., NO. 2022-0807-MTZ (THE "ACTION").
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced it ranked 380th on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year.
Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024DENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter of fiscal 2025, after the market close on Wednesday, November 13, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, November 13, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual SummitDENVER, CO / ACCESSWIRE / October 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024, at 2:00 p.m. Eastern time.
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial ResultsFull year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 million
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable TermsCompany receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in CanadaOnce approved by Health Canada, Adzenys and Cotempla will be the only orally disintegrating, extended-release tablets for the treatment of ADHD commercialized in Canada
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024DENVER, CO / ACCESSWIRE / September 19, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its fiscal 2024 full year and fourth quarter, after the market close on Thursday, September 26, 2024. The Company has scheduled a conference call and webcast that same day, Thursday, September 26, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Sidoti Events, LLC's Virtual August Micro-Cap ConferenceNEW YORK, NY / ACCESSWIRE / August 13, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 14-15, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024DENVER, CO / ACCESSWIRE / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Conference, taking place virtually on Wednesday, August 14, 2024, and Thursday, August 15, 2024.
Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and...
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (
NASDAQAYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (
NASDAQAYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, May 15, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second QuarterDENVER, CO / ACCESSWIRE / February 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (
NASDAQAYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter.
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (
NASDAQAYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December 31, 2023, after the market close on Wednesday, February 14, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, February 14, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer section.
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024DENVER, CO / ACCESSWIRE / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (
NASDAQAYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference taking place virtually on February 1, 2024.
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval SupplementU.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract Manufacturer
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (
NASDAQAYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 for the period ended September 30, 2023, after the market close on Tuesday, November 14, 2023. The Company has scheduled a conference call that same day, Tuesday, November 14, 2023, at 4:30 pm ET, to review the results.
